FindTrial
Sign In

effectiveness and safety of Batroxobin, Tranexamic acid in reduction of blood loss in arthroplasty

effectiveness and safety of Batroxobin, Tranexamic acid in reduction of blood loss in arthroplasty

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017563
Enrollment
Unknown
Registered
2018-08-04
Start date
2018-08-01
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

deep vein thrombosis

Interventions

Group 1:Batroxobin
Group 2:Tranexamic acid

Sponsors

Zhongshan Hospital, Xiamen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 100 Years

Inclusion criteria

Inclusion criteria: primary unilateral TKA

Exclusion criteria

Exclusion criteria: thromboembolism history

Design outcomes

Primary

MeasureTime frame
blood loss;—

Countries

China

Contacts

Public ContactQin Jizheng

Zhongshan Hospital, Xiamen University

qinjizheng@126.com+86 0592-2993081

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026